Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services | News
Search Refinements

Contract Services News

View news from other Pharmaceutical sectors:
1-15 of 2360 results
eFFECTOR partners with Pfizer, Merck to evaluate combination of two immuno-oncology agents
eFFECTOR Therapeutics has entered into a clinical collaboration and supply agreement with Pfizer and Merck to evaluate the combination of two immuno-oncology agents in patients with microsatellite stable colorectal cancer (CRC).
Contract Research & Services > Contract Services > News
Immune Pharmaceuticals signs deal to regain global rights for Ceplene
Immune Pharmaceuticals has signed an agreement with Mylan company Meda to repurchase assets relating to Ceplene, including the right to commercialize it in Europe and to register and commercialize in several other countries.
Contract Research & Services > Contract Services > News
Pfizer to commercialize Basilea's Cresemba drug in Europe
Basilea Pharmaceutica International has signed a license agreement with Pfizer for its marketed antifungal Cresemba (isavuconazole) to treat life-threatening invasive mold infections.
Contract Research & Services > Contract Services > News
OBI Pharma to acquire Threshold's TH-3424 small-molecule prodrug
Taiwan-based OBI Pharma has agreed to acquire Threshold Pharmaceuticals' TH-3424, a novel small-molecule prodrug that selectively targets cancers overexpressing the enzyme aldo-keto reductase 1c3 (AKR1C3).
Contract Research & Services > Contract Services > News
ImmunoGen and Sanofi amend license deals
ImmunoGen and an affiliate of Sanofi have amended their license agreements to cover all compounds developed by the latter using ImmunoGen’s technology.
Contract Research & Services > Contract Services > News
Debiopharm acquires ImmunoGen’s ADC IMGN529/Debio 1562
Debiopharm International has acquired ImmunoGen's IMGN529/Debio 1562, a clinical-stage anti-CD37 ADC for the treatment of patients with B-cell malignancies, such as non-Hodgkin lymphomas (NHL).
Contract Research & Services > Contract Services > News
INC Research, inVentiv agree to merge in $4.6bn deal
By PBR Staff Writer
INC Research has agreed to acquire US-based contract research organization (CRO) inVentiv Health in all stock deal worth nearly $4.6bn.
Contract Research & Services > Contract Services > News
Novartis licenses CAR-T patents from Celyad
Celyad has granted Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents.
Contract Research & Services > Contract Services > News
Akebia expands anemia drug collaboration with Otsuka
By PBR Staff Writer
US-based Akebia Therapeutics has expanded its collaboration with Japan's Otsuka Pharmaceutical on an anemia treatment.
Contract Research & Services > Contract Services > News
Immune Pharmaceuticals licenses cancer treatment's Latin America rights to Pint
Immune Pharmaceuticals has entered into a letter of intent with Pint Pharma regarding license and commercializion of Ceplene in Latin America.
Contract Research & Services > Contract Services > News
PureTech signs licensing and equity deal with Novartis to advance clinical stage mTORC1 programs
PureTech Health has signed a licensing and equity agreement with Novartis to advance two clinical-stage programs targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway.
Contract Research & Services > Contract Services > News
PTC Therapeutics agrees to buy Marathon's DMD drug for $140m
PTC Therapeutics has agreed to acquire all rights to Emflaza (deflazacort) from Marathon Pharmaceuticals.
Contract Research & Services > Contract Services > News
Advaxis licenses antigen delivery technology to Sellas for cancer immunotherapy development
Advaxis has licensed its Lm-based antigen delivery technology to Sellas, under a cancer immunotherapy collaboration that could generate up to $358m for Advaxis.
Contract Research & Services > Contract Services > News
Horizon Discovery signs master service deal with top three global pharmaceutical firm
Horizon Discovery Group has signed a Master Services Agreement (MSA) with a top three global pharmaceutical company, extending support for their drug discovery and development efforts to its full suite of services.
Contract Research & Services > Contract Services > News
Neurotrope signs licensing deal for accelerated synthesis of Alzheimer’s drug Bryostatin-1
Neurotrope has signed a licensing agreement with Stanford University for an accelerated synthesis of Alzheimer's drug bryostatin-1.
Contract Research & Services > Contract Services > News
1-15 of 2360 results